Amneal Pharmaceuticals, Inc.
http://www.amneal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
FTC Sides With Amneal Over Inhaler Patent Dispute With Teva
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.
Payors Take Lead From FTC In Suing BI Over Its Orange Book Patent Listings For Inhalers
Class action complaint alleges Boehringer Ingelheim engaged in a ‘Respimat Orange Book scheme’ to thwart generic competition for Combivent Respimat and Spiriva Respimat that cost payors millions, if not billions, in overcharges.
Amneal ‘Very Excited’ About Biosimilars Future, Looks To Expand Portfolio In 2024
Amneal continues to see a bright future in the biosimilars business as it looks for new portfolio additions, and gets ready for several complex product launches, some even yet to be disclosed, this year.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice